Aytu Q4 FY26 revenue up 6.4% to $16.1M; EXXUA launches with 3,323 scripts

AYTU BIOPHARMA, INC

Q4 FY26 net revenue $16.1M, +6.4% YoY; EXXUA alone contributed $3.9M in first full quarter.
EXXUA Q4 prescriptions 3,323, up ~138% from Q3; June hit record 1,261 scripts; shipments ~4,600 units.
Full-year FY26 revenue $57.6M, down 13.3% YoY, driven by ADHD portfolio decline and Adzenys generic competition.
FY26 net loss $14.3M ($1.16 loss/share) vs $13.6M loss; Adjusted EBITDA -$3.7M vs +$9.2M prior year.
Cash $26.3M at June 30, 2026; warrant amendment cut derivative warrant liabilities by $26.4M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.